HB Wealth Management LLC Has $1.65 Million Stock Position in West Pharmaceutical Services, Inc. $WST

HB Wealth Management LLC lessened its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 25.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,567 shares of the medical instruments supplier’s stock after selling 2,283 shares during the quarter. HB Wealth Management LLC’s holdings in West Pharmaceutical Services were worth $1,646,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in WST. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the fourth quarter worth $25,000. Bayban acquired a new stake in West Pharmaceutical Services in the fourth quarter valued at $27,000. Private Trust Co. NA grew its position in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 61 shares during the period. DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the 4th quarter valued at about $28,000. Finally, International Assets Investment Management LLC acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $31,000. 93.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a report on Friday, May 29th. Stephens reissued an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. KeyCorp upped their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Evercore reaffirmed an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a research report on Monday. Finally, Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $351.91.

Insider Transactions at West Pharmaceutical Services

In other news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Down 0.4%

WST stock opened at $356.15 on Wednesday. West Pharmaceutical Services, Inc. has a fifty-two week low of $206.80 and a fifty-two week high of $367.66. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The stock has a market capitalization of $25.16 billion, a price-to-earnings ratio of 47.61, a PEG ratio of 2.99 and a beta of 1.16. The business’s fifty day moving average price is $324.62 and its two-hundred day moving average price is $280.17.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. During the same quarter in the previous year, the business posted $1.45 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.